Published on
September 15, 2023
- 19:00 GMT
Withdrawn application: Iclusig, ponatinib, Date of withdrawal: 11/08/2023, Post-authorisation
Based on the review of the information and the company’s response to the Agency’s questions, at the time of the withdrawal, the Agency’s provisional opinion was that Iclusig could not have been authorised for the proposed use based on the data submitted. …
Distribution channels:
Healthcare & Pharmaceuticals Industry
